Evaluation of radioiodine therapy with fixed doses of 10 and 15 mCi in patients with Graves' disease;Avaliação da radioiodoterapia com doses fixas de 10 e 15 mCi em pacientes com doença de Graves

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 7, 2007, Pages 1069-1076

  Canadas, Viviane ^a,b   Vilar, Lucio ^a   Moura, Eliane ^a   Brito, Ana ^a   Castellar, Ênio ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b NONE   (Brazil)

Author keywords

Antithyroid drugs; Graves' disease; Hyperthyroidism; Radioiodine

Indexed keywords

EID: 38149019310     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000700008     Document Type: Article

References (46)

1. a ed. Rio de Janeiro: Guanabara Koogan-Medsi, 2006. pp. 274-91.
2. Weetman AP. Medical progress: Graves' disease. N Engl J Med 2000;343:1236-48.
3. Cooper DS. Hyperthyroidism. Lancet 2003;362:459-68.
4. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990;70:1518-24.
5. Pearce EN. Diagnosis and management of thyrotoxicosis. BMJ 2006;332:1369-73.
6. Reid JR, Wheeler SF. Hyperthyroidism: diagnosis and treatment. Am Fam Physician 2005;72:623-30.
7. Bartalena L, Tanda ML, Bogazzi F, Piantanida E, Lai A, Martino E. An update on the pharmacological management of hyperthyroidism due to Graves' disease. Expert Opin Pharmacother 2005;6:851-61.
8. Leech NJ, Dayan CM. Controversies in the management of Graves' disease. Clin Endocrinol (Oxf) 1998;49:273-80.
9. Wemeau JL. Hyperthyroidism: current concepts and management. Rev Prat 2005;55:149-57.
10. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 2005;153:489-98.
11. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991;1:129-35.
12. Marti J, Anton E, Laborda E, Santisteban P. Outcome of Graves disease after radioiodine therapy. An Med Interna 2005;22:303-4.
13. Schussler-Fiorenza CM, Bruns CM, Chen H. The surgical management of Graves' disease. J Surg Res 2006;133:207-14.
14. Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003;88:3474-81.
15. Tamagna EI, Levine GA, Hershman JM. Thyroid hormone concentrations after radioiodine therapy for hyperthyroidism. J Nucl Med 1979;20:387-91.
16. Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf) 2004;61:641-8.
17. Velkeniers B, Vanhaelst L, Cytryn R, Jonckheer MH. Treatment of hyperthyroidism with radioiodine: adjunctive therapy with antithyroid drugs reconsidered. Lancet 1988;1127-9.
18. Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism. Cancer Biother Radiopharm 2005;20:218-23.
19. 131I therapy for Graves' disease. N Engl J Med 1984;311:426-32.
20. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 1995;273:808-12.
21. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003;88:978-83.
22. Jarlov AE, Hegedüs L, Kristensen L, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile? Clin Endocrinol (Oxf) 1995;43:325-9.
23. Ward LS, Filho AC, Menabó E, Ribeiro SRR, Lima MC, Maciel RMB. Estudo da relação custo/efetividade no tratamento da doença de Basedow-Graves. Rev Ass Med Brasil 1986;32:147-54.
24. Streetman DD, Khanderia U. Diagnosis and treatment of Graves disease. Ann Pharmacother 2003;37:1100-9.
25. DeGroot LJ. Radioiodine and the immune system. Thyroid 1997;7:259-63.
26. Hardisty CA, Jones SJ, Hedley AJ, Munro DS, Bewsher PD, Weir RD. Clinical outcome and costs of care in radioiodine treatment of hyperthyroidism. R Coll Physicians Lond 1990;24:36-42.
27. Marcocci C, Gianchecchi D, Masini I, Golia F, Ceccarelli C, Bracci E, et al. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism. J Endocrinol Invest 1990;13:513-20.
28. Hershman JM, Resnick NM. Hypothyroidism and hyperthyroidism. In: Lavin N (ed). Manual of Endocrinology and Metabolism. 2nd ed. Boston: Little, Brown and Company, 1994. pp. 367-80.
29. Bogazzi F, Bartalena L, Campomori A, Brogioni S, Traino C, De Martino F, et al. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease. J Clin Endocrinol Metab 2002;87:4490-5.
30. Gittoes NJ, Franklyn JA. Hyperthyroidism - Current treatment guidelines. Drugs 1998;55:543-53.
31. Bartalena L, Maracocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989;321:1349-52.
32. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73-8.
33. Huysmans D, Hermus A, Edelbroek M, Barentsz J, Corstens F, Kloppenborg P. Radioiodine for nontoxic multinodular goiter. Thyroid 1997;7:235-9.
34. Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves' hyperthyroidism: Treatment with antithyroid drugs, surgery, or radioiodine-A prospective randomized study. J Clin Endocrinol Metab 1996;81:2986-93.
35. Walter MA, Christ-Crain M, Eckard B, Schindler C, Nitzsche EU, Muller-Brand J, et al. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Invest 2004;34:365-70.
36. Erem C, Kandemir N, Hacihasanoglu A, Ersoz HO, Ukinc K, Kocak M. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine 2004;25:55-60.
37. Tan GH, Gharib H. Recurrent hyperthyroidism after radioiodine-induced hypothyroidism: report of two cases and literature review. Endocr Pract 1995;1:158-60.
38. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-17.
39. Graham GD, Burman KD. Radioiodine treatment for Graves' disease. An assessment of its potential risks. Ann Intern Med 1986;105:900-5.
40. Ruchala M, Sowinski J, Dolata M, Junik R, Gembicki M, Skiba A. Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake. Nucl Med Rev Cent East Eur 2005;8:28-32.
41. 131I with pre-treatment with carbimazole for thyrotoxicosis: The gastesheal protocol. Nucl Med Commun 2004;25:675-82.
42. Perros P. Anti-thyroid drug treatment before radioiodine in patients with Graves' disease: soother or menace? Clin Endocrinol (Oxf) 2000;53:1-2.
43. Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 1995; 5:243-7.
44. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid 2004;14:525-30.
45. Hancock L, Tuttle M, LeMar H, Bauman J, Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clin Endocrinol (Oxf) 1997;47:425-30.
46. VA, Gross JL, Maia AL. Effect of methimazole on the efficacy of radioiodine therapy in Graves' hyperthyroidism. J Clin Endocrinol Metab 2001;86:3488-93.